Clinical Trials GPS

Achieve Clinical Research is conducting a randomized clinical study to evaluate the safety, tolerability, and efficacy of a new drug in subjects with moderate to severe Ulcerative Colitis.

Avail is conducting a Phase 2, randomized clinical study to evaluate the efficacy and safety of a new drug in female Subjects with diarrhea-predominant Irritable Bowel Syndrome (IBS).

Avail Clinical is conducting an 11-week, Phase 2 Multicenter, Randomized, Double−Blind, Parallel−Group, Placebo−Controlled Study of a new drug in Subjects with Fibromyalgia (FM).

Achieve Clinical is Conducting a Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of a New Drug for the Treatment of Patients with Fibromyalgia

Achieve is conducting a Phase 3, 12-Week, Randomized-Withdrawal Study to Evaluate the Efficacy and Safety of a new drug for Relief in Patients With Chronic Low Back Pain Who Require Opioid Treatment for an Extended Period of Time

Avail is conducting a 12-week, Phase 2, Randomized Study to Evaluate the Safety and Efficacy of a new drug in Subjects with Chronic Hepatitis C Infection.

Achieve Clinical is conducting a phase III, randomized, double-blind, placebo controlled, parallel group study to evaluate the glycemic and renal efficacy of a new drug for 24 weeks in type 2 diabetes patients.

A randomized, double-blind, placebo-controlled Phase III Trial to evaluate immunogenicity and safety of three consecutive production lots of the IMVAMUNE® smallpox vaccine in healthy...

A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race with Systemic Lupus Erythematosus...

This study is a Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of a new drug in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS).